Biopharmaceutical company Disc Medicine Inc. (IRON) is advancing multiple clinical-stage programs aimed at modifying red blood cell biology, with recent regulatory filings and trial updates placing the company in focus.
The stock closed Tuesday's trading session at $66.08, up 1.57%, with after-hours movement slightly lower at $65.95. Volume reached 370,074 shares, above its average volume of 341,241, reflecting increased activity ahead of several anticipated milestones.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.